WHO concerned over plant of Novartis unit Sandoz


Sandoz, the generic drugs unit of Novartis, has lost World Health Organisation approval for drugs produced at a South African plant due to manufacturing problems, the UN agency said.

The WHO said it considered the plant was not operating in compliance with its manufacturing guidelines and so had recommended suspending procurement of all products made at the site as well as approval of any new products made there.

In a “notice of concern” letter sent to Sandoz earlier this month, the WHO said an inspection in May had revealed 41 deviations from its standards, including failure to prevent contamination and problems with cleaning and disinfection.

It had been forced to act because Sandoz had said the WHO could not conduct a follow-up inspection before the end of 2008.

A Novartis spokesman said Sandoz was working hard to solve the problems at the plant.

“We are doing everything to complete changes as quickly as possible and to reschedule a visit of the WHO by the first quarter of 2009,” the spokesman said.

Last week, US health officials banned dozens of drugs made by India's Ranbaxy Laboratories Ltd after the generic drugmaker failed to fix numerous record-keeping and other operational problems, although the drugs are considered safe. (Reuters)


Farmgate Prices Climb 48% in June Figures

Farmgate Prices Climb 48% in June

Parl't approves 2023 budget Parliament

Parl't approves 2023 budget

Danubius Hotels Appoints Group Director of Development Appointments

Danubius Hotels Appoints Group Director of Development

Muni Council Organizing Meeting to Improve Air Quality City

Muni Council Organizing Meeting to Improve Air Quality


Producing journalism that is worthy of the name is a costly business. For 27 years, the publishers, editors and reporters of the Budapest Business Journal have striven to bring you business news that works, information that you can trust, that is factual, accurate and presented without fear or favor.
Newspaper organizations across the globe have struggled to find a business model that allows them to continue to excel, without compromising their ability to perform. Most recently, some have experimented with the idea of involving their most important stakeholders, their readers.
We would like to offer that same opportunity to our readers. We would like to invite you to help us deliver the quality business journalism you require. Hit our Support the BBJ button and you can choose the how much and how often you send us your contributions.